U
RPRX

UBS’s Repros Therapeutics Inc. RPRX Stock Holding History

UBS’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-800
Closed -$21K – 11504
2013
Q3 		$21K Sell
800
-35,800
-98% -$767K ﹤0.01% 8041
2013
Q2 		$675K Buy
+36,600
New +$646K ﹤0.01% 3765

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

UBS's RPRX Position: Q3 2014 in Review

UBS reduced its Repros Therapeutics Inc. (RPRX) stake by 48% in Q3 2014, selling an estimated $158K and leaving 11,749 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #5822.

UBS first reported a position in RPRX in Q2 2013 and has held it in 5 quarters since. The position peaked at $388K in Q2 2014. 75 funds tracked by Wall St. Rank hold RPRX as of Q3 2014.

  • UBS held 11,749 shares of Repros Therapeutics Inc. worth $116K as of Q3 2014.
  • UBS sold 10,684 Repros Therapeutics Inc. shares in Q3 2014, an estimated $158K.
  • Repros Therapeutics Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5822 holding.
  • UBS first reported a position in Repros Therapeutics Inc. in Q2 2013 and has held it in 5 quarters since.
  • UBS's Repros Therapeutics Inc. position peaked at $388K in Q2 2014.
  • 75 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.